Navigation Links
Cambrex Reports Second Quarter 2012 Results
Date:8/1/2012

EAST RUTHERFORD, N.J., Aug. 1, 2012 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports second quarter results for the period ended June 30, 2012.

Highlights

  • Reported sales increased by 14.3%, and excluding the impact of foreign currency, sales increased 20.2% compared to the second quarter of 2011. 
  • EBITDA increased 45.9% to $19.2 million in the quarter, compared to $13.2 million in the second quarter of 2011. 
  • Debt, net of cash was $58.2 million at the end of the quarter, an improvement of $5.1 million during the quarter which includes a negative $1.1 million currency impact on foreign cash balances.
  • Full year sales guidance, excluding the impact of foreign currency, revised to an increase of between 10% and 13% versus 2011 (prior guidance between 2% and 6%) and full year EBITDA guidance revised to be between $54 and $58 million (prior guidance between $47 and $53 million).
  • Second Quarter of 2012 Operating Results
    Sales in the second quarter of 2012 of $77.1 million were 14.3% higher than the second quarter of 2011.  Foreign exchange unfavorably impacted sales by 5.9%.  The increase is primarily due to higher volumes of controlled substances and generic active pharmaceutical ingredients ("APIs").

    Gross margins in the second quarter of 2012 increased to 36.9% from 28.2% in the second quarter of 2011.  Foreign currency favorably impacted second quarter 2012 margins by 1.5%.  The increase is due to higher production volumes, leading to increased plant efficiencies and favorable product mix. 

    Selling, General and Administrative Expenses in the second quarter of 2012 were $12.0 million compared to $9.2 million in the same period last year.  The increase is primarily the result of increased personnel related expenses, accruals for higher annual incentiv
    '/>"/>

    SOURCE Cambrex Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Cambrex to Announce Fourth Quarter 2011 Financial Results on February 6, 2012
    2. Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results
    3. Neurocrine Biosciences Reports Second Quarter 2012 Results
    4. Pharmos Corporation Reports Second Quarter 2012 Results
    5. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
    6. SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
    7. Neogen reports year end results
    8. Cepheid Reports 2012 Second Quarter Results
    9. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
    10. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
    11. Prosperous Agriculture Reports Outstanding Sales Result for First Half of 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
    (Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
    (Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
    (Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
    Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
    ... Guidance New Launches Should Contribute ... Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced ... Quarter and Six Month Results, For the second quarter ... and a net loss of $20.1 million, or $0.60 per ...
    ... Aug. 7 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" ... into an arrangement agreement (the "Arrangement Agreement") dated,August ... ("Calyx"), a,wholly-owned subsidiary of Chromos, and Modatech Systems ... agreement have agreed to effect a plan,of arrangement ...
    ... CITY, Aug. 7 Thousands of AIDS activists,gathered today ... a key event of the XVII International AIDS Conference. ... protections,for people living with HIV and those most affected ... use drugs, and men who,have sex with men., ...
    Cached Biology Technology:Par Pharmaceutical Reports Second Quarter 2008 Results 2Par Pharmaceutical Reports Second Quarter 2008 Results 3Par Pharmaceutical Reports Second Quarter 2008 Results 4Par Pharmaceutical Reports Second Quarter 2008 Results 5Par Pharmaceutical Reports Second Quarter 2008 Results 6Par Pharmaceutical Reports Second Quarter 2008 Results 7Par Pharmaceutical Reports Second Quarter 2008 Results 8Chromos enters into an Arrangement Agreement 2Chromos enters into an Arrangement Agreement 3Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response 2Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response 3Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response 4
    (Date:4/23/2014)... researcher has shed light on how an estimated one ... outback have become reviled as pests and culled on ... and Sustainability Institute at the University of Exeter,s Penryn ... from their historic role helping to create the country,s ... , The deserts of the Australian outback are a ...
    (Date:4/23/2014)... is leading a 2 million Food Standards Agency (FSA) ... premises and industry workers. , Norovirus outbreaks can ... a batch of frozen strawberries infected 11,000 people in ... understanding of which strains cause infection and which foods ... , Researchers will produce data that will help ...
    (Date:4/22/2014)... a five-year, $3 million study to determine whether an ... of dissolved organic matter (DOM) through the Connecticut River ... composition and water quality of the watershed and Long ... Foundation,s MacroSystems Biology program, researchers will collect data from ... Canada and runs through five U.S. states, before emptying ...
    Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3
    ... State University researcher has demonstrated that a variety of environmental ... animal but the next three generations of its offspring. , ... the way genes turn on and offthe epigenetic effect studied ... on in the current issue of the online journal ...
    ... sizes. Scientists have discovered simple rules that control leaf shape during ... able to accurately emulate leaf growth from a bud. "A ... said lead author Samantha Fox from the John Innes Centre on ... bud, not flat with a pointed tip." By creating a ...
    ... On March 9, the New York Academy of Sciences ... of Established Regulatory Guidance." This full-day conference will explore ... challenges for follow-on versions of complex drugs. , On ... draft guidelines for implementing the Biologics Price Competition and ...
    Cached Biology News:Effects of environmental toxicants reach down through generations 2First model of how buds grow into leaves 2Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference 2
    Prepared from plasminogen by activation with immobilized human uPA...
    Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
    Human GFR alpha-4 Affinity Purified Polyclonal Ab...
    Rat CNTF R alpha Affinity Purified Polyclonal Ab...
    Biology Products: